For more information, seewww.astrazeneca.com/investor-relations.html. Table 1: Key elements of Total Revenue performance in Q4 2023 % Change Table 2: Key elements of financial performance in Q4 2023 Table 3: Pipeline highlights since prior results announcement Upcoming pipeline catalysts For a tab...
Discover how we champion inclusion and diversity at AstraZeneca We have 199 projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres ...
AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debi...
AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, September 9-12, 2023.
Zilurgisertibsurvived a pipeline cull in May 2023, when Incyte scrapped six R&D prospects, including one that was in a phase 3 trial for a rare form of anemia. At the time, Incyte CEO Hervé Hoppenot said the move was made to focus on “programs that can have a high impact for patien...
Leveraging Absci’s deep experience with generative AI tools in pharmaceutical processes, executives of both companies have expressed optimism for the future of cancer treatment. Absci has 15 active programs ranging from strategic partnerships to internal pipeline candidates, generating 3 billion protein-pr...
Ruud Dobber, Ph.D, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: “Our broad pipeline and portfolio of inhaled and biologic medicines are the cornerstone of our bold ambition to ...
Since 2005, AstraZeneca has achieved an almost six-fold improvement in the proportion of its pipeline molecules that have advanced from preclinical investigation to completion of Phase III clinical trials - from 4% to 23%. This improvement moves AstraZeneca well above the...
AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers,plunking down $2 billionto acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therapies, AstraZeneca gains the crucial supply chai...
During the quarter, the company said at its annual investor day that it believes the drugs in its development pipeline can boost revenue to $80 billion annually by 2030, compared to $45 billion in 2023. AstraZeneca (AZN) posted better-than-expected results for the second quarter and lifted ...